专稿

肿瘤基础研究对促进新时期癌症防治工作具有关键作用

  • 张赟 ,
  • 刘芝华
展开
  • 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院,分子肿瘤学国家重点实验室,北京 100021
张赟,研究员,研究方向为肿瘤微环境及肿瘤转移分子机制,电子信箱:yunzhang@cicams.ac.cn

收稿日期: 2023-06-28

  修回日期: 2023-09-06

  网络出版日期: 2023-09-28

基金资助

科技部重点研发计划项目(2021YFC2501000)

Basic research holds the key for successful cancer prevention and treatment

  • ZHANG Yun ,
  • LIU Zhihua
Expand
  • State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Received date: 2023-06-28

  Revised date: 2023-09-06

  Online published: 2023-09-28

摘要

癌症是全球范围内最主要的健康问题之一。研发癌症防治的新技术、新药物、新疗法,是中国人民和全人类共同的迫切需求,也是全球科技竞争的重点方向。肿瘤基础研究对癌症防治工作起着关键作用。指出了当前中国癌症领域“从0到1”研发诊断治疗新靶点、新药物的创新能力仍与世界一流水平有差距,面临的关键问题不是研究成果转化程度不高,而是基础研究的深度广度不足。建议为促进新时期癌症防治工作,应当高度重视肿瘤基础研究,通过稳定的经费支持、合理的项目设置、健全产学研合作机制、促进国际合作等措施支持高水平肿瘤基础研究的发展。

本文引用格式

张赟 , 刘芝华 . 肿瘤基础研究对促进新时期癌症防治工作具有关键作用[J]. 科技导报, 2023 , 41(18) : 6 -10 . DOI: 10.3981/j.issn.1000-7857.2023.18.001

Abstract

Cancer is one of the major health challenges worldwide. It is in urgent need to develop new technologies, new medicine, and new strategies to prevent and treat cancer. Cancer research is one key area in today’s global scientific competition. Importantly, basic research holds the key for successful cancer prevention and treatment. It is the major reason why we are behind the world-class level in developing novel cancer targets and drugs. In order to promote cancer prevention and treatment in the new era, we should pay special attention to cancer basic research. High-level cancer basic research could be supported through stable financial funding, wise project setting, improved industry-university-research cooperation mechanisms, and effective international cooperation.

参考文献

[1] Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[2] Zheng R S, Zhang S W, Zeng H M, et al. Cancer incidence and mortality in China, 2016[J]. Journal of the National Cancer Center, 2022, 2(1): 1-9.
[3] Cai Y, Xue M, Chen W Q, et al. Expenditure of hospital care on cancer in China, from 2011 to 2015[J]. Chinese Journal of Cancer Research, 2017, 29(3): 253-262.
[4] Rous P. A transmissible avian neoplasm (Sarcoma of the common fowl)[J]. Journal of Experimental Medicine, 1910, 12: 696-705.
[5] Bishop J M. Cellular oncogenes and retroviruses[J]. Annual Review of Biochemistry, 1983, 52: 301-354.
[6] Shih C, Padhy L C, Murray M, et al. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts[J]. Nature, 1981, 290(5803): 261-264.
[7] Friend S H, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma[J]. Nature, 1986, 323(6089): 643-646.
[8] Loeb L A, Harris C C. Advances in chemical carcinogenesis: A historical review and prospective[J]. Cancer Research, 2008, 68(17): 6863-6872.
[9] Hanahan D, Weinberg R A. Hallmarks of cancer: The next generation[J]. Cell, 2011, 144(5): 646-674.
[10] Hanahan D. Hallmarks of cancer: New dimensions[J]. Cancer Discov, 2022, 12(1): 31-46.
[11] Miller D R. A tribute to Sidney Farber: The father of modern chemotherapy[J]. British Journal of Haematology, 2006, 134(1): 20-26.
[12] Poggetto E D, Ho I, Balestrieri C, et al. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis[J]. Science, 2021, 373(6561): eabj0486.
[13] Lawrence R, Watters M, Davies C R, et al. Circulating tumour cells for early detection of clinically relevant cancer[J]. Nature Reviews Clinical Oncology, 2023, 20(7): 487-500.
[14] Tivey A, Church M, Rothwell D, et al. Circulating tu⁃mour DNA-looking beyond the blood[J]. Nature Reviews Clinical Oncology, 2022, 19(9): 600-612.
[15] Wang D, Liu B, Zhang Z. Accelerating the understanding of cancer biology through the lens of genomics[J]. Cell, 2023, 186(8): 1755-1771.
[16] Seton-Rogers S. KRAS-G12C in the crosshairs[J]. Nature Reviews Cancer, 2020, 20(1): 33.
[17] Sharma P, Goswami S, Raychaudhuri D, et al. Immune checkpoint therapy-current perspectives and future directions[J]. Cell, 2023, 186(8): 1652-1669.
[18] NCI research project grants funding and R01 paylines (FY 2023) [EB/OL]. [2023-08-28]. https://visualsonline. cancer.gov/details.cfm?imageid=12747.
[19] Cancer moonshot SM[EB/OL]. [2023-08-28]. https://www. cancer. gov/research/key-initiatives/moonshot-cancer-initiative.
[20] Cancer grand challenges[EB/OL]. [2023-08-28]. https://cancergrandchallenges.org.
文章导航

/